Introduction
============

Gastric cancer is one of the most common types of malignancy globally ([@b1-ol-0-0-9819]). Improvements in diagnosis and treatment have resulted in greater long-term survival for patients with early gastric cancer; however, the prognosis for patients with advanced gastric cancer remains relatively poor, with locally advanced and widespread metastatic disease associated with a high mortality rate ([@b2-ol-0-0-9819]). Despite the need for an improved understanding on how gastric cancer metastasizes, the mechanisms underlying gastric cancer progression remain unclear.

Gastric cancer has the ability to spread locally via direct invasion through the gastric wall into adjacent tissue; it then has the ability to metastasize to regional lymph nodes and distant organs through the lymphatic and venous vessels. Recent evidence has emerged suggesting that acquisition of invasiveness in cancer cells is accompanied by the loss of epithelial features and the gain of a mesenchymal phenotype, in a process termed the epithelial-mesenchymal transition (EMT) ([@b3-ol-0-0-9819]).

A variety of molecules have been identified in tumor samples as EMT-associated markers, including the epithelial marker E-cadherin ([@b4-ol-0-0-9819]) and the mesenchymal marker *Vimentin* ([@b5-ol-0-0-9819]). Transcriptional factors, including the zinc-finger protein Snail ([@b6-ol-0-0-9819]), the basic helix-loop-helix protein Twist ([@b7-ol-0-0-9819]) and the E-box-binding protein ZEB1/2 ([@b8-ol-0-0-9819],[@b9-ol-0-0-9819]), are also involved in regulating EMT-associated changes. It has been previously reported that matrix metalloproteinases serve key roles in the invasion and metastasis of gastric cancer ([@b10-ol-0-0-9819]--[@b13-ol-0-0-9819]).

Expression of the actin-binding protein L-plastin in SW480 cells was recently demonstrated to cause a downregulation of E-cadherin and an increase in invasiveness ([@b14-ol-0-0-9819]). Furthermore, it was previously reported that the Plastin3 *(PLS3)* gene, which is known to code for an actin bundling protein that inhibits cofilin-mediated depolymerization of actin, may be used as a marker for circulating tumor cells; *PLS3* has been demonstrated to serve an important role in the EMT of colorectal carcinoma cells ([@b15-ol-0-0-9819]). However, there are few reports to data regarding the clinical significance of *PLS3* in epithelial malignancies.

In the present study, the clinical significance of *PLS3* in gastric cancer was identified as an independent prognostic factor and the association between the EMT markers Cadherin1 *(CDH1), Vimentin* and *PLS3* was indicated. Furthermore, it was demonstrated in an *in vitro* study that *PLS3* serves a key role in invasion and migration in gastric cancer.

Materials and methods
=====================

### Clinical samples and cell lines

Primary gastric carcinoma and adjacent normal gastric epithelial tissues were obtained from a total of 163 patients who underwent gastric resection, without preoperative treatment, at The Oita Prefectural Hospital (Oita, Japan) or The Kyushu University Beppu Hospital (Beppu, Japan) between 1993 April and 2003 December. All of the obtained tissue samples were cut and immediately placed into RNAlater^®^ (Takara Bio, Inc., Otsu, Japan), then frozen in liquid nitrogen and kept at −80°C until RNA extraction. Written informed consent was obtained from all of the patients and the protocol of the study was approved by the Ethics Committee of Kyushu University (Fukuoka, Japan). Clinicopathological information, including age (range, 40--87 years), sex, pathology, differentiation and tumor-node metastasis classification, was available for all patients. The tumor size was calculated under the microscope by pathologists. The median overall survival (OS) time was 32 months and ranged from 1--144 months.

Human gastric cancer cell lines NUGC3, NUGC4, MKN7, MKN45, MKN74 and AGS were provided by the Cell Resource Centre for Biomedical Research Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan). All cells were grown in RPMI-1640 medium (Cambrex Corporation, East Rutherford, NJ, USA), supplemented with 10% foetal bovine serum (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 2 mmol/l glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Cambrex Corporation); this was followed by incubation at 37°C in a humidified chamber with 5% CO~2~.

### Immunohistochemistry

Immunohistochemical studies of PLS3 were performed on formalin-fixed paraffin-embedded surgical sections (5-µm thick) obtained from 43 patients with gastric cancer treated at the Kyushu University Beppu Hospital (Beppu, Japan). Tissue sections were deparaffinised and boiled in 0.01 mol/l sodium citrate buffer (pH 9.0; 0.01 ml of 1 M disodium citrate and 99.99 ml of 1 M trisodium citrate) in a microwave for 10 min at 500 W for antigen retrieval and then washed in phosphate-buffered saline (PBS). The primary antibody used was goat anti-PLS3 (C15; cat no. sc-16555; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), which was diluted to a ratio of 1:100 and incubated with the slides for 15 min at room temperature. All tissue sections were immunohistochemically stained with the avidin-biotin-peroxidase LASB2 kit (cat. no. K0675; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) according to the protocol of the manufacturer, and were counterstained with haematoxylin at room temperature for 3 min. Representative photomicrographs were captured with a Nikon Eclipse E800 microscope equipped with a Nikon DXM1200 digital camera (Nikon instruments, Melville, NY, USA). Slides were observed under light microscopy at ×40 magnification, and five regions were selected for every slide at random. The degree of differentiation was independently evaluated by two of the authors (Dr Junji Kurashige and Dr Kosuke Mima) using a blinded protocol design, with the observers having no knowledge of the clinical outcome or any other clinicopathological data. For evaluation of the PLS3 expression, the staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) or 3 (strong) as previously indicated ([@b16-ol-0-0-9819]).

### Total RNA isolation and first-strand cDNA synthesis

Total RNA was isolated from frozen tissue samples and cultured cell lines using a modified acid-guanidine-phenol-chloroform method as described previously ([@b15-ol-0-0-9819]). The purity and concentration of all RNA samples were evaluated using an absorbance ratio of 260/280 nm with a NanoDrop^™^ ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Total RNA was reverse transcribed with M-MLV RT, according to the manufacturer\'s protocol (Invitrogen; Thermo Fisher Scientific, Inc.).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The expression levels of *PLS3, CDH1* and *Vimentin* were determined using a LightCycler^®^ 480 Probes Master kit (Roche Molecular Diagnostics, Pleasanton, CA, USA), according to the manufacturer\'s instructions. The primer sequences used in RT-qPCR were as follows: *PLS3* forward 5′-GAAACTTACACCCTTCATCATTCAG-3′, reverse 5′-TTCTGCACCAATGTTCACAAC-3′ and universal probe no. 29; *CDH1* forward 5′-GGCCAGGAAATCACATCCTA-3′, reverse 5′-GGCAGTGTCTCTCCAAATCC-3′ and universal probe no. 36; *Vimentin* forward 5′-TACAGGAAGCTGCTGGAAGG-3′, reverse 5′-ACCAGAGGGAGTGAATCCAG-3′ and universal probe no. 13; *GAPDH* forward 5′-AGCCACATGCTCAGACAC-3′, reverse 5′-AATACGACCAAATCCGTTGACT-3′ and universal probe no. 60. All RT-qPCR reactions were run in a LightCycler^®^ 480 system II (Roche Molecular Diagnostics). The relative amounts of *PLS3, CDH1* and *Vimentin* were measured using the 2^−∆∆Cq^ method ([@b17-ol-0-0-9819]) and normalized to GAPDH. All RT-qPCR reactions were performed in triplicate.

### PLS3 RNA interference

Small interfering RNAs (siRNA) against *PLS3* no. 1 (5′-CAGCAACGGAUUCAUUUGUTT-3′) and 2 (5′-CUGCUUAGAUGGGCAAACUTT-3′), along with control non-targeting siRNA were obtained from Ambion (Thermo Fisher Scientific, Inc.). The non-silencing control siRNA, which has no sequence homology to any known human gene sequence, was used as a control with non-specific effects for all experiments. The siRNA oligomer was diluted with Opti-MEM I without serum (Invitrogen; Thermo Fisher Scientific, Inc.). The diluted siRNA oligomer was mixed with diluted Lipofectamine^®^ RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.), and incubated for 15 min at room temperature to allow siRNA-Lipofectamine^®^ RNAiMAX complexes to form. The optimal amount of siRNA used for transfection was determined to be 20 nmol/l. Diluted logarithmic growth phase NUGC3 and AGS cells without antibiotics were seeded at a density of 2×10^5^ cells/well in a final volume of 2.5 ml into 6-well flat-bottom microtiter plates. The cells were incubated in a humidified atmosphere (37°C and 5% CO~2~). The assay was performed after a 72-h incubation.

### Migration and invasion assay

Cell migration was assessed using The BD Falcon^™^ FluoroBlok^™^ 24 Multiwell Insert system (BD Bioscience, San Jose, CA, USA). For a period of 24 h prior to the assay, cells were transfected with *PLS3* siRNA or a negative control siRNA. The NUGC3 and AGS cells (1.0×10^4^) were placed in the upper chamber of a 24-well plate with serum-free RPMI-1640 medium. The lower chamber was filled with 750 µl medium with 10% foetal bovine serum, in which the serum acted as a chemoattractant, and the cell migration plate was incubated in a humidified atmosphere (37°C and 5% CO~2~). After a 48 h incubation, the upper chamber was transferred into a second 24-well plate containing 500 µl/well of 4 µg/ml calcein AM in HBSS (Invitrogen; Thermo Fisher Scientific, Inc.) and incubated for 1 h (37°C and 5% CO~2~). Invasive cells that migrated through the membrane were evaluated using a fluorescence plate reader at excitation/emission wavelengths of 485/535 nm. Each independent experiment was performed three times. NUGC3 cell invasion was assessed using the BD BioCoat^™^ Tumor Invasion system 24-Multiwell (BD Bioscience, San Jose, CA, USA) and the same procedure as that used for migration.

### Statistical analysis

All experiments were performed ≥3. Continuous variables were expressed as the mean ± standard deviation. The association between the expression of *PLS3* and the patient clinicopathological characteristics was analysed using a Student\'s t-test or χ^2^ analysis. The OS time curves were plotted according to the Kaplan-Meier method and the generalized log-rank test was applied to compare the survival curves. P\<0.05 was considered to indicate a statistically significant difference. All tests were performed using JMP^®^ software 8th edition (SAS Institute, Inc., Cary, NC, USA).

Results
=======

### Immunohistochemistry of PLS3 expression

Expression of the PLS3 protein was evaluated by immunohistochemical analysis of resected gastric cancer specimens using the anti-PLS3 antibody. PLS3 staining was notably strong in poorly differentiated gastric cancer tissues ([Fig. 1A](#f1-ol-0-0-9819){ref-type="fig"}) and in the budding foci in well differentiated gastric cancer ([Fig. 1B](#f1-ol-0-0-9819){ref-type="fig"}). On the other hand, PLS3 staining was weak in differentiated gastric cancer tissues ([Fig. 1C](#f1-ol-0-0-9819){ref-type="fig"}). Overall, the staining was primarily located within the cytoplasm.

### PLS3 mRNA expression and clinicopathological characteristics

Expression levels of *PLS3* were examined in 163 gastric cancer clinical samples using RT-qPCR, with quantified values used to calculate *PLS3/GAPDH* ratios. In the specimens with strong staining, the mRNA expression levels of *PLS3* were significantly higher compared with that in the weak staining group (P\<0.05; [Fig. 1D](#f1-ol-0-0-9819){ref-type="fig"}). The 163 patients with gastric cancer were divided into two groups according to the median *PLS3* mRNA expression level: 82 of the cases were placed in the high *PLS3* expression group, and the remaining 81 cases were placed into the low *PLS3* expression group. The association between patient clinicopathological characteristics and *PLS3* expression is summarized in [Table I](#tI-ol-0-0-9819){ref-type="table"}. *PLS3* expression was significantly associated with cancer differentiation (well and moderately differentiated vs. poorly differentiated and others; P=0.010), depth of tumour invasion (T1 and T2 vs. T3 and T4; P=0.029), distant metastasis (present vs. absent; P=0.010) and cancer staging (stage I and II vs. III and IV; P=0.002). By contrast, there was no significant association between *PLS3* expression and age (P=0.143), sex (P=0.953), lymph node metastasis (present vs. absent; P=0.825), venous invasion (present vs. absent; P=0.788) and peritoneal metastasis (present vs. absent; P=0.900).

### Survival analysis for the expression of PLS3

Analysis of the 5-year OS revealed that the high *PLS3* expression group had a significantly poorer prognosis compared with the low expression group (P=0.012; [Fig. 2](#f2-ol-0-0-9819){ref-type="fig"}). In a univariate Cox regression analysis, the high *PLS3* expression group displayed significantly higher overall mortality \[hazard ratio (HR), 2.211; 95% confidence interval (CI), 1.299--3.764; P=0.012; [Table II](#tII-ol-0-0-9819){ref-type="table"}\] compared with the low *PLS3* expression group. Variables with P\<0.05 from univariate analysis were selected for multivariate analysis with the Cox\'s proportional hazard model. In a multivariate Cox regression analysis for OS time, including tumour depth, tumour size, lymph node metastasis, venous invasion, peritoneal metastasis and *PLS3* expression, high *PLS3* expression was indicated to be an independent prognostic factor (HR, 1.770; 95% CI, 1.020--3.074; P=0.042; [Table II](#tII-ol-0-0-9819){ref-type="table"}).

### Inhibition of PLS3 gene expression with PLS3 siRNA in human gastric cancer cells

Knockdown of *PLS3* mRNA was performed in NUGC3 and AGS gastric cancer cells, which have the highest *PLS3* mRNA expression levels among eight different gastric cancer cell lines examined (NUGC3, NUGC4, MKN7, MKN45, MKN74, AGS) (data not shown). Evaluation of the expression levels following *PLS3* siRNA transfection confirmed that *PLS3* mRNA expression in cells transfected with *PLS3* siRNA no. 1 and 2 was lower compared with that in cells transfected with the negative control siRNA ([Fig. 3A](#f3-ol-0-0-9819){ref-type="fig"}). The transfected cells were used to investigate whether *PLS3* knockdown altered migration and invasion. NUGC3 and AGS cells transfected with *PLS3* siRNA exhibited reduced migratory abilities (P\<0.05; [Fig. 3B](#f3-ol-0-0-9819){ref-type="fig"}), and NUGC cells were significantly less invasive (P\<0.05; [Fig. 3C](#f3-ol-0-0-9819){ref-type="fig"}), compared with those cells transfected with the negative control siRNA. These results indicate that knockdown of *PLS3* suppressed the migration and invasion of gastric cancer cells *in vitro*.

### Association between CDH1 and Vimentin mRNA expression, and PLS3 mRNA expression in gastric cancer

The association between the expression of *PLS3*, and that of *CDH1* and *Vimentin* in patients with gastric cancer was investigated. The 163 gastric cancer cases were classified into high and low expression groups, according to the median *PLS3* mRNA expression levels determined by RT-qPCR. As presented in [Fig. 4A](#f4-ol-0-0-9819){ref-type="fig"}, *Vimentin* mRNA expression levels were significantly increased in the high *PLS3* expression group (n=82), compared within the low *PLS3* expression group (n=81; P\<0.01); however, there was no significant difference in *CDH1* mRNA expression between the high and low *PLS3* expression groups. Similarly, *Vimentin* mRNA was significantly decreased in NUGC3 cells transfected with siRNA no. 1 and 2, compared with the negative control ([Fig. 4B](#f4-ol-0-0-9819){ref-type="fig"}); however, *CDH1* mRNA expression was not significantly different in NUGC3 cells transfected with siRNA compared with the negative control group ([Fig. 4B](#f4-ol-0-0-9819){ref-type="fig"}).

Discussion
==========

In the present study, it was revealed that the patients with a high *PLS3* expression had a significantly poorer prognosis compared with those with a low *PLS3* expression. In addition, *PLS3* expression was associated with cancer differentiation, depth of tumour invasion and distant metastasis. Furthermore, it was demonstrated that there was a significant positive association between *PLS3* and *Vimentin* expression in gastric cancer. It was concluded that downregulation of *PLS3* in gastric cancer cells was associated with the inhibition of cellular invasion and migration.

The *PLS3* gene, located on chromosome Xq23, encodes a protein that functions to polymerize actin fibers through the inhibition of cofilin-mediated actin depolymerization ([@b18-ol-0-0-9819]); however, there is limited knowledge regarding the biology of *PLS3* and its relevance to solid cancer development and progression. A previous study demonstrated that colorectal carcinoma cell lines overexpressing *PLS3* acquire invasiveness through the downregulation of E-cadherin ([@b19-ol-0-0-9819]). Furthermore, supportive evidence that PLS3 may be involved in EMT via TGFB1 stimulation was revealed. In addition, the results of the present study demonstrated that PLS3 is associated with colorectal cancer metastasis and cancer stemness ([@b15-ol-0-0-9819]). In the present study, it was determined that *Vimentin* expression is significantly higher in the group with high *PLS3* expression than in the low expression group, and the downregulation of *PLS3* caused a decrease in the expression of *Vimentin* mRNA; however, *CDH1* exhibited no significant changes in expression levels between the high and low *PLS3* expression groups. Additionally, it was revealed that there was a strong association between *PLS3* expression and distant metastasis in gastric cancer. The findings of the present study propose that *PLS3* is a key factor in EMT, which in turn leads to regulation of *Vimentin*. Plastin are a recently described family of actin-binding proteins, which have been implicated in invasion and metastasis ([@b18-ol-0-0-9819]). The present study provides the first evidence for the clinical significance of *PLS3* in primary gastric cancer. Conversely, the present study identified no significant associations between *PLS3* expression and peritoneal dissemination; however, a strong association between *PLS3* expression and distant metastasis was determined. Therefore, the results suggest that *PLS3* expression may be used in predicting hematogenous metastasis. Furthermore, *PLS3* was demonstrated to regulate the invasion and migration in gastric cancer, *PLS3*-targeted therapy may be more effective in blocking distant metastasis of gastric cancer.

It was reported that the presence of *PLS3* in peripheral blood in colorectal cancer cases was significantly associated with disease-free survival and OS time, and *PLS3*-expressing cells were detected in the peripheral blood of \~33% of Japanese patients with colorectal cancer ([@b15-ol-0-0-9819]). It was expected that the high *PLS3* expression levels in the peripheral blood and bone marrow of patients with advanced gastric cancer could be detected, and therefore the expression of *PLS3* in preoperative peripheral blood and bone marrow from the patients with gastric cancer could be investigated; however, there was no significant association between *PLS3* expression and cancer staging in the peripheral blood and bone marrow, and there was no significant difference between gastric cancer and healthy volunteers (data not presented). The results in the current study revealed that *PLS3* serves an important role in the invasion of gastric cancer cells in primary tumors; however, there was no clinicopathological significance to the presence of the *PLS3* gene in the circulation in the gastric cancer cases. This discrepancy may have indicated the differences in hematogenous pathways of cancer progression between colorectal cells and gastric cancer cells. *PLS3* is not a useful circulating tumour cell marker in patients with gastric cancer; therefore, the expression of *PLS3* in gastric cancer may be lower than in colorectal cancer. A conclusive marker to detect circulating tumor cells has not yet been established for gastric cancer and further studies are required to identify other novel circulating tumour markers of gastric cancer.

In conclusion, the present study demonstrated that high expression levels of *PLS3* are independently associated with poor prognosis, and that *PLS3* serves an important role in EMT through the inhibition of cellular migration and invasion, and the regulation of *Vimentin* expression in gastric cancer.
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![PLS3 expression in representative samples of gastric cancer. The majority of staining in the cancer cells was located in the cytoplasm. (A) PLS3 staining was strong in poorly differentiated gastric cancer tissues (×40 magnification) and (B) in budding foci in well differentiated gastric cancer (top panel, ×40 magnification; bottom panel, ×200 magnification). (C) PLS3 staining was weak in differentiated gastric cancer tissues (×200 magnification). (D) In the strong staining specimens, the mRNA expression levels of *PLS3* were significantly higher than in the weak staining group. *PLS3*, plastin3; por1, porin 1; tub1, α-tubulin 1.](ol-17-02-2393-g00){#f1-ol-0-0-9819}

![Kaplan-Meier survival curves of high and low *PLS3* expression groups. A total of 163 gastric cancer cases were classified into two groups according to the median *PLS3* mRNA expression level determined by reverse transcriptase-quantitative polymerase chain reaction. The high expression group consists of 82 patients, with the low expression group containing 81. The OS time of patients with gastric cancer in each group is depicted according to the level of *PLS3* mRNA expression. The survival rate for patients in the high *PLS3* expression group was significantly lower than that for patients in the low expression group (P=0.012). *PLS3, plastin3*; OS, overall survival.](ol-17-02-2393-g01){#f2-ol-0-0-9819}

![Suppression of *PLS3* by siRNA reduced the migration and invasion of gastric cancer cells. (A) *PLS3* mRNA expression in NUGC3 and AGS cells transfected with NUGC3 siRNA no. 1 and 2 was measured by reverse transcriptase-quantitative polymerase chain reaction and compared with cells transfected with a negative control siRNA. (B) Migration assays of NUGC3 and AGS cells transfected with *PLS3* siRNA, compared with cells transfected with a negative control siRNA. (C) Invasion assays of NUGC3 cells transfected with *PLS3* siRNA compared with cells transfected with a negative control siRNA. Each bar represents the mean ± standard error of the mesan of samples measured in triplicate, and each experiment was repeated ≥3. \*P\<0.05. *PLS3, plastin3*; siRNA, small interfering RNA.](ol-17-02-2393-g02){#f3-ol-0-0-9819}

![Association of *CDH1* and *Vimentin* expressions with *PLS3* expression in gastric cancer. (A) In the high *PLS3* expression group (n=82), the expression of *Vimentin* mRNAs was significantly increased compared with that in the low *PLS3* expression group (n=81; P\<0.01). There was no significant difference in *CDH1* mRNA expression between the high and low *PLS3* expression group. (B) In NUGC3 cells transfected with siRNA *PLS3* no. 1 or 2, the expression of *Vimentin* mRNA was significantly decreased compared with the negative control; however, there was no significant difference in *CDH1* mRNA expression between NUGC3 cells transfected with siRNA and the negative control cells. *PLS3, plastin3;* NS, no significance; siRNA, small interfering RNA; *CDH1*, Cadherin1.](ol-17-02-2393-g03){#f4-ol-0-0-9819}

###### 

*PLS3* mRNA expression and clinicopathological features.

                                        *PLS3* mRNA expression               
  ------------------------- ----------- ------------------------ ----------- ----------------------------------------------------
  Age (years)                                                                0.143
    Mean ± SD               65.9±11.2   64.6±10.9                67.2±11.9   
  Sex                                                                        0.953
    Male                    105         53 (64.6)                52 (64.2)   
    Female                  58          29 (35.4)                29 (35.8)   
  Differentiation                                                            0.010^[a](#tfn1-ol-0-0-9819){ref-type="table-fn"}^
    Well/moderately         76          30 (36.6)                46 (56.8)   
    Poorly/others           87          52 (63.4)                35 (43.2)   
  Depth of tumor invasion                                                    0.029^[a](#tfn1-ol-0-0-9819){ref-type="table-fn"}^
    T1-2                    59          23 (28.0)                36 (44.4)   
    T3-4                    104         59 (72.0)                45 (55.6)   
  Lymph node metastasis                                                      0.825
    Absent                  57          28 (34.1)                29 (35.8)   
    Present                 106         54 (65.9)                52 (64.2)   
  Lymphatic invasion                                                         0.788
    Absent                  58          30 (36.6)                28 (34.6)   
    Present                 105         52 (63.4)                53 (65.4)   
  Venous invasion                                                            0.900
    Absent                  120         60 (73.2)                60 (74.1)   
    Present                 43          22 (26.8)                21 (25.9)   
  Peritoneal metastasis                                                      0.806
    Absent                  138         69 (84.1)                67 (82.7)   
    Present                 27          13 (15.9)                14 (17.3)   
  Distant metastasis                                                         0.010^[a](#tfn1-ol-0-0-9819){ref-type="table-fn"}^
    Absent                  150         71 (86.6)                79 (97.5)   
    Present                 13          11 (13.4)                2 (2.5)     
  Stage                                                                      0.002^[a](#tfn1-ol-0-0-9819){ref-type="table-fn"}^
    I--II                   93          37 (45.1)                56 (69.1)   
    III--IV                 70          45 (54.9)                25 (30.9)   

P\<0.05. Staging was classified by Union for International Cancer Control 7th edition system ([@b20-ol-0-0-9819]). mRNA, messenger RNA; T, tumour; SD, standard deviation; *PLS3, Plastin3*.

###### 

Univariate and multivariate analysis of clinicopathological features for 5-year OS (Cox\'s proportional regression model).

                                                 Univariate analysis   Multivariate analysis                                                                                 
  ---------------------------------------------- --------------------- ----------------------- ------------------------------------------------------ ------- -------------- ------------------------------------------------------
  Age years (\>65/65≥)                           0.765                 0.460--1.272            0.301                                                                         
  Sex (male/female)                              0.893                 0.513--1.553            0.688                                                                         
  Differentiation (well, moderate/poor, other)   1.375                 0.820--2.305            0.228                                                                         
  T (1,2/3,4)                                    3.239                 1.681--3.514            \<0.001^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^   1.301   0.575--2.944   0.577
  Tumor size (\<50/≥50 mm)                       2.068                 1.225--3.490            0.007^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^     0.835   0.445--1.570   0.527
  Lymph node metastasis (absent/present)         4.387                 2.149--8.958            \<0.001^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^   2.876   1.318--6.274   0.008^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^
  Venous invasion (absent/present)               3.386                 2.013--5.696            \<0.001^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^   1.734   0.975--3.086   0.061^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^
  Lymphatic invasion (absent/present)            3.748                 1.835--7.656            \<0.001^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^                          
  Peritoneal metastasis (absent/present)         6.644                 3.706--11.912           \<0.001^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^   3.553   1.873--6.740   \<0.001^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^
  Stage (I, II/III, IV)                          5.460                 3.096--9.629            \<0.001^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^                          
  *PLS3* expression (low/high)                   2.211                 1.299--3.764            0.012^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^     1.770   1.020--3.074   0.042^[a](#tfn2-ol-0-0-9819){ref-type="table-fn"}^

P\<0.05; HR, hazard ratio; CI, confidence interval; T, tumor; OS, overall survival; *PLS3, Plastin3*.
